Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Antipsychotic drug trifluoperazine inhibits growth of mycobacterial isolates

July 15, 1998

Merck & Co.'s new tachykinin antagonists

July 14, 1998

NPY Y1 receptor agonists from Ortho with anxiolytic activity

July 14, 1998

Interneuron initiates phase III CerAxon study and licenses citicoline patent rights to Ferrer

July 14, 1998

Sabcomeline treatment results in cognitive enhancement in nonhuman primates

July 14, 1998

Neuroprotective effects of YM-39558, a potential treatment for stroke

July 14, 1998

Antagonists of neurotrophin activity described by Allelix for pain, epilepsy and AD

July 13, 1998

Merck's new tachykinin receptor antagonists useful for pain, inflammation, etc.

July 13, 1998

Cephalon and Medtronic renew ITB copromotion agreement

July 13, 1998

Fentanyl delivery via SmartMist provides effective analgesia

July 13, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.